SAN DIEGO, March 06, 2019 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage
biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D.,
J.D., President and Chief Executive Officer, is scheduled to present at two upcoming investor conferences:
- Cowen and Company Health Care Conference in Boston on March 12, 2019 at 9:20 a.m. ET / 6:20 a.m. PT; and
- Oppenheimer Healthcare Conference in New York on March 19, 2019 at 2:10 p.m. ET / 11:10 a.m. PT.
A live audio webcast and replay of each presentation will be available in the Investors section of Kura Oncology's website
at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the
treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where
there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from
treatment. Kura’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, for which the Company has initiated a
registration-directed trial of tipifarnib in recurrent or metastatic patients with HRAS mutant HNSCC. In addition, tipifarnib is
being evaluated in multiple other Phase 2 clinical trials in solid tumor and hematologic indications. Kura’s pipeline also includes
KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, which is anticipated to
enter into a Phase 1 clinical trial in the second quarter of 2019. For additional information about Kura Oncology, please visit the
Company’s website at www.kuraoncology.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such
as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to
identify forward-looking statements. These forward-looking statements are based upon Kura Oncology’s current expectations and
involve assumptions that may never materialize, or may prove to be incorrect. Actual results could differ materially from those
anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation,
risks and uncertainties associated with Kura Oncology’s business and finances in general, and the other risks described in Kura
Oncology’s periodic and other filings with the SEC. All forward-looking statements contained in this press release speak only as of
the date on which they were made. Kura Oncology undertakes no obligation to update such statements to reflect events that occur or
circumstances that exist after the date on which they were made
Contacts
Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com
Investors:
Robert H. Uhl
Managing Director
Westwicke Partners, LLC
(858) 356-5932
robert.uhl@westwicke.com
Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com
![Primary Logo](https://resource.globenewswire.com/media/ee889fc4-c7c7-4823-8c42-aad89c075028/small/kura-oncology-logo.jpg)